The Echelon-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A plus CHP) Vs CHOP in frontline treatment of pts with CD30-positive peripheral t-cell lymphoma
Horwitz, S. M. Savage, K. J. Illidge, Timothy M Plyer, S. Advani, R. Shustov, A. R. Bartlett, N. L. Pro, B. Jacobsen, E. D. Koch, R.
Horwitz, S. M.
Savage, K. J.
Illidge, Timothy M
Plyer, S.
Advani, R.
Shustov, A. R.
Bartlett, N. L.
Pro, B.
Jacobsen, E. D.
Koch, R.
Citations
Altmetric:
Abstract
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Horwitz SM, Savage KJ, Timillidge, Plyer S, Advani R, Shustov AR, et al. The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398800133.